Item 1.01 Entry into a Material Definitive Agreement

First Amendment to Huadong License Agreement

On January 14, 2021, vTv Therapeutics LLC ("vTv LLC"), a subsidiary of vTv Therapeutics Inc., entered into the First Amendment to License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Huadong") (the "First Amendment") to amend the License Agreement previously entered into between vTv LLC and Huadong on December 21, 2017 (the "Original Agreement"). The First Amendment eliminates vTv LLC's obligation to sponsor a Phase 2 Multi-Region Clinical Trial and corresponding obligation to contribute up to $3.0 million in support of such trial. The First Amendment also reduces the total potential development and regulatory milestone payments of $25.0 million under the Original Agreement by $3.0 million.

The foregoing description of the License Amendment is qualified in its entirety by reference to the First Amendment, which the Company intends to file with the SEC as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses